683 Capital Management’s Contineum Therapeutics CTNM Stock Holding History

683 Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,000	Closed	-$718K	–	249
2026 Q1	$718K	Sell	55,000 -36,442	-40%	-$489K	0.04%	159
2025 Q4	$1.05M	Buy	+91,442	New	+$1.04M	0.05%	136

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

683 Capital Management's CTNM Position: Q2 2026 in Review

683 Capital Management sold out of Contineum Therapeutics (CTNM) in Q2 2026, closing a stake of 55,000 shares — an estimated $718K sold.

683 Capital Management first reported a position in CTNM in Q4 2025 and held it in 2 quarters. The position peaked at $1.05M in Q4 2025. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

683 Capital Management reported no remaining Contineum Therapeutics position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 55,000 Contineum Therapeutics shares in Q2 2026, an estimated $718K.
683 Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and held it in 2 quarters.
683 Capital Management's Contineum Therapeutics position peaked at $1.05M in Q4 2025.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.